Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients
Author(s) -
Nicolas Argy,
Solène Le Gal,
Romain Coppée,
Zehua Song,
William Vindrios,
Laurent Massias,
WeiChun Kao,
Carola Hunte,
Yazdan Yazdanpanah,
JeanChristophe Lucet,
Sandrine Houzé,
Jérôme Clain,
Gilles Nevez
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy154
Subject(s) - medicine , atovaquone , outbreak , opportunistic infection , virology , immunology , microbiology and biotechnology , human immunodeficiency virus (hiv) , viral disease , biology , plasmodium falciparum , malaria
Although trimethoprim-sulfamethoxazole is the more efficient drug for prophylactic and curative treatment of pneumocystosis, atovaquone is considered a second-line prophylactic treatment in immunocompromised patients. Variations in atovaquone absorption and mutant fungi selection after atovaquone exposure have been associated with atovaquone prophylactic failure. We report here a Pneumocystis jirovecii cytochrome b (cyt b) mutation (A144V) associated with such prophylactic failure during a pneumocystosis outbreak among heart transplant recipients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom